Cargando…
Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
Neisseria meningitidis causes severe invasive meningococcal diseases (IMDs) in humans including meningitis and septicemia, responsible for serious clinical conditions and leading to life-long disabilities and death. Serogroup B dominates IMDs burden in Italy, accounting for over 60% of total cases....
Autores principales: | SIGNORELLI, C., CHIESA, V., ODONE, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore SPA
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755121/ https://www.ncbi.nlm.nih.gov/pubmed/26788733 |
Ejemplares similares
-
Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction
por: Martinelli, Domenico, et al.
Publicado: (2015) -
Invasive Meningococcal Disease and Meningococcal Serogroup B Vaccination in Adults and Their Offspring: Knowledge, Attitudes, and Practices in Italy (2019)
por: Riccò, Matteo, et al.
Publicado: (2023) -
Parental awareness and utilization of meningococcal serogroup B vaccines in the United States
por: Srivastava, Amit, et al.
Publicado: (2020) -
Meningococcal serogroup B vaccines: Estimating breadth of coverage
por: Donald, Robert G. K., et al.
Publicado: (2016) -
2. Understanding Patient Preferences for Meningococcal Serogroup B Vaccines in the United States
por: Johnson, Reed, et al.
Publicado: (2020)